US20080312239A1 - Methods for the treatment of erectile dysfunction using fispemifene - Google Patents

Methods for the treatment of erectile dysfunction using fispemifene Download PDF

Info

Publication number
US20080312239A1
US20080312239A1 US12/138,560 US13856008A US2008312239A1 US 20080312239 A1 US20080312239 A1 US 20080312239A1 US 13856008 A US13856008 A US 13856008A US 2008312239 A1 US2008312239 A1 US 2008312239A1
Authority
US
United States
Prior art keywords
fispemifene
pde
inhibitor
week
testosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/138,560
Other languages
English (en)
Inventor
Robert L. Zerbe
Alexander Bridges
Risto Lammintausta
Rochelle Hanley
Stuart Dombey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QuatRx Pharmaceuticals Co
Original Assignee
QuatRx Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QuatRx Pharmaceuticals Co filed Critical QuatRx Pharmaceuticals Co
Priority to US12/138,560 priority Critical patent/US20080312239A1/en
Assigned to QUATRX PHARMACEUTICALS COMPANY reassignment QUATRX PHARMACEUTICALS COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LAMMINTAUSTA, M.D., RISTO, BRIDGES, PH.D., ALEXANDER, DOMBEY, M.B., F.R.C.P., STUART, ZERBE, M.D., ROBERT L., HANLEY, M.D., ROCHELLE
Publication of US20080312239A1 publication Critical patent/US20080312239A1/en
Priority to US12/795,986 priority patent/US20100261729A1/en
Priority to US13/848,325 priority patent/US10500166B2/en
Priority to US16/672,112 priority patent/US20200060991A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US12/138,560 2007-06-13 2008-06-13 Methods for the treatment of erectile dysfunction using fispemifene Abandoned US20080312239A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/138,560 US20080312239A1 (en) 2007-06-13 2008-06-13 Methods for the treatment of erectile dysfunction using fispemifene
US12/795,986 US20100261729A1 (en) 2007-06-13 2010-06-08 Methods for the treatment of erectile dysfunction using fispemifene
US13/848,325 US10500166B2 (en) 2007-06-13 2013-03-21 Methods for the treatment of erectile dysfunction using fispemifene
US16/672,112 US20200060991A1 (en) 2007-06-13 2019-11-01 Methods for the treatment of erectile dysfunction using fispemifene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94370607P 2007-06-13 2007-06-13
US12/138,560 US20080312239A1 (en) 2007-06-13 2008-06-13 Methods for the treatment of erectile dysfunction using fispemifene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/795,986 Continuation US20100261729A1 (en) 2007-06-13 2010-06-08 Methods for the treatment of erectile dysfunction using fispemifene

Publications (1)

Publication Number Publication Date
US20080312239A1 true US20080312239A1 (en) 2008-12-18

Family

ID=40070738

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/138,560 Abandoned US20080312239A1 (en) 2007-06-13 2008-06-13 Methods for the treatment of erectile dysfunction using fispemifene
US12/795,986 Abandoned US20100261729A1 (en) 2007-06-13 2010-06-08 Methods for the treatment of erectile dysfunction using fispemifene
US13/848,325 Expired - Fee Related US10500166B2 (en) 2007-06-13 2013-03-21 Methods for the treatment of erectile dysfunction using fispemifene
US16/672,112 Abandoned US20200060991A1 (en) 2007-06-13 2019-11-01 Methods for the treatment of erectile dysfunction using fispemifene

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/795,986 Abandoned US20100261729A1 (en) 2007-06-13 2010-06-08 Methods for the treatment of erectile dysfunction using fispemifene
US13/848,325 Expired - Fee Related US10500166B2 (en) 2007-06-13 2013-03-21 Methods for the treatment of erectile dysfunction using fispemifene
US16/672,112 Abandoned US20200060991A1 (en) 2007-06-13 2019-11-01 Methods for the treatment of erectile dysfunction using fispemifene

Country Status (2)

Country Link
US (4) US20080312239A1 (fr)
WO (1) WO2008157335A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147264A1 (fr) * 2016-02-25 2017-08-31 Aspen Park Pharmaceuticals, Inc. Forme posologique orale des deux isomères de clomiphène et procédé d'utilisation pour traiter un hypogonadisme secondaire

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481847C2 (ru) * 2011-06-16 2013-05-20 Государственное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию" Способ лечения гнойно-септических осложнений при аденоме простаты

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750576A (en) * 1994-09-07 1998-05-12 Orion-Yhtyma Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US6512002B2 (en) * 2000-01-12 2003-01-28 Pfizer Inc. Methods of treatment for premature ejaculation in a male
US6576645B1 (en) * 1999-11-16 2003-06-10 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20060293294A1 (en) * 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
US20070104743A1 (en) * 2005-11-09 2007-05-10 Hormos Medical Ltd. Formulations of fispemifene
US7368480B2 (en) * 2001-07-09 2008-05-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2578852A1 (fr) * 2004-09-03 2006-03-09 Hormos Medical Corporation Utilisation d'un modulateur selectif du recepteurs des oestrogenes dans la fabrication d'une preparation pharmaceutique utilisee dans une methode de traitement ou de prevention des insuffisances endrogeniques
CN106038572A (zh) * 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750576A (en) * 1994-09-07 1998-05-12 Orion-Yhtyma Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US6576645B1 (en) * 1999-11-16 2003-06-10 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US6512002B2 (en) * 2000-01-12 2003-01-28 Pfizer Inc. Methods of treatment for premature ejaculation in a male
US7368480B2 (en) * 2001-07-09 2008-05-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US20060293294A1 (en) * 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
US20070104743A1 (en) * 2005-11-09 2007-05-10 Hormos Medical Ltd. Formulations of fispemifene

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147264A1 (fr) * 2016-02-25 2017-08-31 Aspen Park Pharmaceuticals, Inc. Forme posologique orale des deux isomères de clomiphène et procédé d'utilisation pour traiter un hypogonadisme secondaire

Also Published As

Publication number Publication date
US20100261729A1 (en) 2010-10-14
US20130217696A1 (en) 2013-08-22
US10500166B2 (en) 2019-12-10
WO2008157335A2 (fr) 2008-12-24
WO2008157335A3 (fr) 2009-03-19
US20200060991A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
US11771682B2 (en) AR+ breast cancer treatment methods
Bostwick et al. Antipsychotic‐induced hyperprolactinemia
AU2001286995B2 (en) Method for treating erectile dysfunction and increasing libido in men
KR20240011237A (ko) 우울증 치료를 위한 에스케타민
Wang et al. Clozapine-induced myocarditis: role of catecholamines in a murine model
AU2013225869B2 (en) Combination therapy for treating androgen deficiency
US20180221389A1 (en) Natural combination hormone replacement formulations and therapies
US20160346295A1 (en) Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US20200060991A1 (en) Methods for the treatment of erectile dysfunction using fispemifene
AU2013221478B2 (en) Selective estrogen receptor modulators with short half-lives and uses thereof
KR20050074896A (ko) 우울증 치료용 안드로겐 제약 조성물 및 방법
CA3131929A1 (fr) Esketamine pour le traitement de la depression
JP2022546456A (ja) 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
US20230302015A1 (en) Natural combination hormone replacement formulations and therapies
AU2017394679A1 (en) Natural combination hormone replacement formulations and therapies
Cazzaniga et al. Erectile Dysfunction
TW202415363A (zh) 用於治療憂鬱症的艾司氯胺酮(esketamine)
Price et al. 20 Treatment of erectile dysfunction

Legal Events

Date Code Title Description
AS Assignment

Owner name: QUATRX PHARMACEUTICALS COMPANY, MICHIGAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZERBE, M.D., ROBERT L.;BRIDGES, PH.D., ALEXANDER;LAMMINTAUSTA, M.D., RISTO;AND OTHERS;REEL/FRAME:021305/0912;SIGNING DATES FROM 20080617 TO 20080619

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION